Institut Carnot OPALE
keyboard_backspaceBack to Home
Contact
Institut de Recherche Saint-Louis, Hôpital Saint-Louis, 1, avenue Claude Vellefaux
75010 Paris
France
Responsable du Business Development
About us
The OPALE Carnot Institute is a consortium of 27 entities representing most of France's academic expertise in the research and development of therapeutic and diagnostic solutions for leukemia and related diseases. With no international equivalent, it offers healthcare companies a unique and comprehensive range of services to accelerate innovation and enhance its valorization across the entire R&D value chain.
OPALE aims to foster research partnerships between its entities and socio-economic players, including healthcare companies, to address their needs.
Business offer
Institut Carnot OPALE offers its expertise in the development of CAR-T cells across the entire R&D value chain: identification of new therapeutic targets, preclinical development (in vitro & in vivo), biomarker research, immunomonitoring, biomanufacturing (early clinical phases), clinical development (phases I to III and ATU), national CAR-T registry.
OPALE offers its partners a one-stop shop for research and development of new advanced therapy drugs for leukemia and related diseases, regardless of the size of the company and the nature of the project.
Activities
- Research Unit
- Cluster / Association
- Oncology
- Hematology
- Immunology
- Cell origin
- Single donor
- Pool of donors
- Cell Banking
- IPs
- MSC
- CD34 + HSC cells
- Apheresis
- Target cell isolation
- Differentiated Cell
- Safety donor-derived therapies
- Cell modification
- Cell Activation
- Ex Vivo & In Vivo Strategy
- Ex Vivo & In Vivo Strategy
- CMC/analytical quality assessment, quality control
- Sterility
- Deviations
- Contaminants detection
- Bioproduction engineering
- Cell Expansion
- Stirred tank Bioreactor
- Wave bioreactor
- Cell factory
- Microcarrier-based culture
- Organoids culture
- Capsules culture
- Scale-Up
- Process optimization
- Automated manufacturing
- On-line monitoring
- Automated high throughput microbioreactor system
- Non-GMP expansion
- GMP expansion
- Other
- Target Identification
- Assay development in in-vitro & in-vivo models
- Cell procurement
- Autologous
- Ex Vivo & In Vivo Strategy
- Ex Vivo & In Vivo Strategy
- Bioproduction/CMC/Analytical Quality Assessment, Quality Control
- Bioproduction
- Scale-Up
- Automated manufacturing
- Non-GMP pilot batch
- GMP batch
- Sterility
- Quality control
- Contaminants detection
